<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "8: expenditures", fill: "#e6e6fa"},
{source: "8: expenditures", target: "8: commercialize", fill: "#e6e6fa"},
{source: "8: commercialize", target: "8: commercialization", fill: "#e6e6fa"},
{source: "8: expenditures", target: "14: Angiomax ", fill: "#008000"},
{source: "14: Angiomax ", target: "14: sales growth", fill: "#008000"},
{source: "14: sales growth", target: "14: slower than", fill: "#008000"},
{source: "14: slower than", target: "14: cannot assure", fill: "#008000"},
{source: "14: cannot assure", target: "14: increased sales", fill: "#008000"},
{source: "14: increased sales", target: "14: marketing efforts", fill: "#008000"},
{source: "14: marketing efforts", target: "14: expanded label will", fill: "#008000"},
{source: "14: expanded label will", target: "14: higher revenues", fill: "#008000"},
{source: "14: Angiomax ", target: "30: development", fill: "#1034a6"},
{source: "30: development", target: "30: Angiomax ", fill: "#1034a6"},
{source: "30: Angiomax ", target: "30: additional", fill: "#1034a6"},
{source: "30: additional", target: "30: indications", fill: "#1034a6"},
{source: "30: indications", target: "30: clevidipine", fill: "#1034a6"},
{source: "30: clevidipine", target: "30: cangrelor", fill: "#1034a6"},
{source: "30: cangrelor", target: "30: manufacturing", fill: "#1034a6"},
{source: "30: manufacturing", target: "30: regulatory", fill: "#1034a6"},
{source: "30: regulatory", target: "30: acquisition", fill: "#1034a6"},
{source: "30: acquisition", target: "30: additional product candidates by us will", fill: "#1034a6"},
{source: "30: additional product candidates by us will", target: "30: commitment", fill: "#1034a6"},
{source: "30: development", target: "99: regulatory approval", fill: "#abcdef"},
{source: "99: regulatory approval", target: "99: clinical data", fill: "#abcdef"},
{source: "99: clinical data", target: "99: product manufacturing processes", fill: "#abcdef"},
{source: "99: product manufacturing processes", target: "99: facilities", fill: "#abcdef"},
{source: "99: facilities", target: "99: regulatory authorities", fill: "#abcdef"},
{source: "99: regulatory authorities", target: "99: each therapeutic indication", fill: "#abcdef"},
{source: "99: each therapeutic indication", target: "99: products safety", fill: "#abcdef"},
{source: "99: regulatory approval", target: "123: Risks Related ", fill: "#dea5a4"},
{source: "123: Risks Related ", target: "123: Dependence ", fill: "#dea5a4"},
{source: "123: Dependence ", target: "123: depend on single suppliers", fill: "#dea5a4"},
{source: "123: depend on single suppliers", target: "123: Angiomax ", fill: "#dea5a4"},
{source: "123: Angiomax ", target: "123: clevidipine", fill: "#dea5a4"},
{source: "123: clevidipine", target: "123: cangrelor bulk drug", fill: "#dea5a4"},
{source: "123: cangrelor bulk drug", target: "123: different single suppliers", fill: "#dea5a4"},
{source: "123: different single suppliers", target: "123: manufacture", fill: "#dea5a4"},
{source: "123: manufacture", target: "123: capacity", fill: "#dea5a4"},
{source: "123: capacity", target: "123: manufacture them", fill: "#dea5a4"},
{source: "123: Risks Related ", target: "START_HERE", fill: "#dea5a4"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bivalirudin">Bivalirudin</a></td>
      <td>Bivalirudin (Bivalitroban), sold under the brand names Angiomax and Angiox and manufactured by The Medicines Company, is a direct thrombin inhibitor (DTI).Chemically, it is a synthetic congener of the naturally occurring drug hirudin, found in the saliva of the medicinal leech Hirudo medicinalis.\nBivalirudin lacks many of the limitations seen with indirect thrombin inhibitors, such as heparin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Eric_Topol">Eric Topol</a></td>
      <td>Eric Jeffrey Topol (born 26 June 1954) is an American cardiologist, scientist, and author. He is the founder and director of the Scripps Research Translational Institute, a professor of Molecular Medicine at The Scripps Research Institute, and a senior consultant at the Division of Cardiovascular Diseases at Scripps Clinic in La Jolla, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_drugs:_An–Ap">List of drugs: An–Ap</a></td>
      <td>This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_direct_thrombin_inhibitors">Discovery and development of direct thrombin inhibitors</a></td>
      <td>Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clevidipine">Clevidipine</a></td>
      <td>Clevidipine (INN, trade name Cleviprex) is a dihydropyridine calcium channel blocker indicated for the reduction of  blood pressure when oral therapy is not feasible or not desirable. Clevidipine is used IV only and practitioners titrate this drug to lower blood pressure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Calcium_channel_blocker_toxicity">Calcium channel blocker toxicity</a></td>
      <td>Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists are a group of medications that disrupt the movement of calcium (Ca2+) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cocaine">Cocaine</a></td>
      <td>Cocaine (from French: cocaïne, from Spanish: coca, ultimately from Quechua: kúka) is a tropane alkaloid and stimulant drug obtained primarily from the leaves of two coca species native to South America, Erythroxylum coca and Erythroxylum novogranatense. It is most commonly used as a recreational drug and euphoriant.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Calcium_channel_blocker">Calcium channel blocker</a></td>
      <td>Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists are a group of medications that disrupt the movement of calcium (Ca2+) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Amitriptyline">Amitriptyline</a></td>
      <td>Amitriptyline, sold under the brand name Elavil among others, is a tricyclic antidepressant primarily used to treat cyclic vomiting syndrome (CVS), major depressive disorder and a variety of pain syndromes from neuropathic pain to fibromyalgia to migraine and tension headaches. Due to the frequency and prominence of side effects, amitriptyline is generally considered a \nsecond-line therapy for these indications.The most common side effects are dry mouth, drowsiness, dizziness, constipation, and weight gain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lidocaine">Lidocaine</a></td>
      <td>Lidocaine, also known as lignocaine and sold under the brand name Xylocaine among others, is a local anesthetic of the amino amide type. It is also used to treat ventricular tachycardia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Antihypertensive_drug">Antihypertensive drug</a></td>
      <td>Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure). Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Topiramate">Topiramate</a></td>
      <td>Topiramate, sold under the brand name Topamax among others, is a carbonic anhydrase inhibitor medication used to treat epilepsy and prevent migraines. It has also been used in alcohol dependence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lorazepam">Lorazepam</a></td>
      <td>Lorazepam, sold under the brand name Ativan among others, is a benzodiazepine medication. It is used to treat anxiety disorders, trouble sleeping, severe agitation, active seizures including status epilepticus, alcohol withdrawal, and chemotherapy-induced nausea and vomiting.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>You should     <font color="blue">carefully</font> consider the risks and <font color="blue">uncertainties described</font> below in addition     to the other information included or <font color="blue">incorporated by reference</font> in this     annual report</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occur, our business,     <font color="blue">financial condition</font> or results of <font color="blue"><font color="blue">operations</font> would likely suffer</font></td>
    </tr>
    <tr>
      <td>In that     case, the <font color="blue">trading price</font> of our <font color="blue"><font color="blue">common stock</font> could fall</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to Our Financial Results       We have a history of net losses and may not maintain <font color="blue"><font color="blue">profitability</font> on</font> an     <font color="blue">annual basis</font>       Except for the year ended <font color="blue">December </font>31, 2004, we have <font color="blue">incurred net losses on</font>     an <font color="blue">annual basis</font> since our inception</td>
    </tr>
    <tr>
      <td>We incurred a net loss for the year     ended <font color="blue">December </font>31, 2005 of dlra7dtta8 million</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had an     <font color="blue">accumulated deficit</font> of approximately dlra304dtta9 million</td>
    </tr>
    <tr>
      <td>We expect to make     substantial <font color="blue"><font color="blue">expenditure</font>s</font> to further develop and <font color="blue">commercialize</font> our products,     including costs and expenses associated with <font color="blue">clinical trial</font>s, <font color="blue">regulatory</font>     approvals and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Although we achieved <font color="blue">profitability</font> in 2004,     we were not able to maintain <font color="blue">profitability</font> in 2005 and <font color="blue">will likely</font> need to     <font color="blue">generate <font color="blue">significantly</font> greater revenues</font> in <font color="blue">future periods</font> to achieve and     maintain <font color="blue">profitability</font> in light of our planned <font color="blue"><font color="blue">expenditure</font>s</font></td>
    </tr>
    <tr>
      <td>We remain     unsure as to when we will achieve <font color="blue">profitability</font> again, if at all, or whether     we will maintain <font color="blue">profitability</font> for any substantial period of time</td>
    </tr>
    <tr>
      <td>If we     fail to achieve <font color="blue">profitability</font> or maintain <font color="blue"><font color="blue">profitability</font> on</font> a quarterly or     <font color="blue">annual basis</font> within the time frame expected <font color="blue">by investors</font> or securities     analysts, the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> may decline</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       Our business is very <font color="blue"><font color="blue">dependent</font> on</font> the <font color="blue">commercial success</font> of <font color="blue">Angiomax </font>      <font color="blue">Angiomax </font>is our <font color="blue">only commercial product</font> and, we expect, <font color="blue">will account</font> for     almost  all of our revenues for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The commercial     success of <font color="blue">Angiomax </font><font color="blue">will <font color="blue">depend upon</font></font>:       ·       its continued acceptance by <font color="blue">regulators</font>, physicians, patients and     other  key  decision-makers  as a safe, therapeutic and cost-<font color="blue">effective</font>     <font color="blue">alternative</font>  to heparin and other <font color="blue">products used</font> in <font color="blue">current practice</font> or     currently being developed;       ·        our ability to expand the <font color="blue"><font color="blue">indication</font>s</font> for which we can market     Angiomax; and       ·       the extent to which we and our <font color="blue">international</font> <font color="blue">distribution</font> partners     are successful in marketing Angiomax</td>
    </tr>
    <tr>
      <td>The rate of <font color="blue">Angiomax </font><font color="blue">sales growth</font> was <font color="blue">slower than</font> we expected in 2005, and     we <font color="blue">cannot assure</font> you that our <font color="blue">increased sales</font> and <font color="blue">marketing efforts</font> or     <font color="blue">expanded label will</font> result in <font color="blue">higher revenues</font> or income</td>
    </tr>
    <tr>
      <td>If <font color="blue">Angiomax </font>is not     <font color="blue">commercially successful</font>, we will have to <font color="blue">find <font color="blue">additional</font> sources</font> of funding     or curtail or <font color="blue">cease <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>In addition, our inventory of <font color="blue">Angiomax </font>    increased  from dlra27dtta3 million at <font color="blue">December </font>31, 2004 to dlra48dtta0 million at     <font color="blue">December </font>31,  2005</td>
    </tr>
    <tr>
      <td>If sales of <font color="blue">Angiomax </font>were to decline, we could be     required to make an allowance for excess or <font color="blue">obsolete inventory</font> or increase     our accrual for <font color="blue">product returns</font></td>
    </tr>
    <tr>
      <td>Our revenues are <font color="blue">substantially</font> <font color="blue"><font color="blue">dependent</font> on</font> a limited number of domestic     <font color="blue">wholesalers</font> and <font color="blue">international</font> <font color="blue">distributors</font> to which we sell Angiomax, and     such revenues may <font color="blue">fluctuate from quarter</font> to <font color="blue">quarter <font color="blue">based on</font></font> the buying     patterns of these <font color="blue">wholesalers</font> and <font color="blue">distribution</font> partners and the levels of     inventory they maintain       We sell <font color="blue">Angiomax </font>primarily to a limited number of <font color="blue">domestic medical</font> and     <font color="blue">pharmaceutical</font> <font color="blue">wholesalers</font> with <font color="blue">distribution</font> centers located <font color="blue">throughout</font> the     <font color="blue"><font color="blue">United States</font> </font>and several <font color="blue">international</font> <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td>During the year ended     <font color="blue">December </font>31, 2005, <font color="blue">revenues from</font> the sale of <font color="blue">Angiomax </font>to our three largest     US <font color="blue">wholesalers</font> totaled approximately 90prca of our net revenue and sales to     one of our <font color="blue">international</font> partners totaled nearly 5prca of our net revenue</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">reliance on</font> a small number of <font color="blue">wholesalers</font> and <font color="blue">distributors</font> could cause our     revenues to <font color="blue">fluctuate from quarter</font> to <font color="blue">quarter <font color="blue">based on</font></font> the <font color="blue">buying patterns</font>     of these <font color="blue">wholesalers</font> and <font color="blue">distributors</font>, regardless of <font color="blue">underlying hospital</font>     demand</td>
    </tr>
    <tr>
      <td>For instance, if <font color="blue">inventory levels</font> at <font color="blue">wholesalers</font> and <font color="blue">distributors</font>     are too high, they may seek to reduce their <font color="blue"><font color="blue">inventory levels</font> by reducing</font>     <font color="blue">purchases from us</font></td>
    </tr>
    <tr>
      <td>In 2005, we <font color="blue">agreed with</font> our largest <font color="blue">wholesalers</font> to enter     into  fee-for-service  <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>As a result of these <font color="blue">restructured</font>     <font color="blue">arrangements</font>,  we expect our three largest <font color="blue">wholesalers</font> to reduce their     <font color="blue">Angiomax </font><font color="blue">inventory levels</font> to an average of four to <font color="blue">six weeks by</font> the end of     the <font color="blue">first quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>In <font color="blue">implementing</font> the <font color="blue">inventory reduction</font>, we     estimate  that  our  three largest <font color="blue">wholesalers</font> reduced their aggregate     <font color="blue">inventories</font> of <font color="blue">Angiomax </font>by approximately dlra26dtta0 million over the last two     quarters of 2005, which had an adverse effect on our revenue</td>
    </tr>
    <tr>
      <td>We expect     these <font color="blue">wholesalers</font> to reduce their aggregate <font color="blue">inventories</font> of <font color="blue">Angiomax </font>by     approximately dlra13dtta0 million in <font color="blue">first quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>The timing of the     <font color="blue">inventory reduction</font>, and the reduction in product sales in any quarter, may     <font color="blue">vary depending on</font> the end-user demand for the product and the actions of our     <font color="blue">wholesalers</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">restructured</font>  <font color="blue">arrangements</font>  with <font color="blue">wholesalers</font> may be     <font color="blue">terminated on</font> short notice, <font color="blue">generally</font> 30 days, and we <font color="blue">cannot assure</font> you that     our planned <font color="blue">inventory reduction</font> will be gradual or successful</td>
    </tr>
    <tr>
      <td>In addition,     if any of these <font color="blue">wholesalers</font> or <font color="blue">distributors</font> fails to pay us on a timely     basis or at all, our <font color="blue">financial position</font> and results of <font color="blue"><font color="blue">operations</font> could</font> be     <font color="blue"><font color="blue">materially</font> <font color="blue"><font color="blue">adversely affect</font>ed</font></font></td>
    </tr>
    <tr>
      <td>Failure to achieve our revenue targets or raise <font color="blue">additional</font> funds in the     <font color="blue">future may</font> require us to delay, reduce the scope of, or <font color="blue">eliminate one</font> or     more of our planned <font color="blue">activities</font>       We will need to <font color="blue">generate <font color="blue">significantly</font> greater revenues</font> to achieve and     maintain <font color="blue"><font color="blue">profitability</font> on</font> an <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of <font color="blue">Angiomax </font>for     <font color="blue">additional</font>  <font color="blue"><font color="blue">indication</font>s</font>, <font color="blue">clevidipine</font> and <font color="blue">cangrelor</font>, including clinical     trials,  <font color="blue">manufacturing</font>  <font color="blue">development</font>  and <font color="blue">regulatory</font> approvals, and the     <font color="blue">acquisition</font> and <font color="blue">development</font> of <font color="blue">additional</font> product <font color="blue">candidates</font> by us will     require a <font color="blue">commitment</font> of substantial funds</td>
    </tr>
    <tr>
      <td><font color="blue">Our       </font>23     ______________________________________________________________________       future funding <font color="blue">requirements</font>, which may be <font color="blue"><font color="blue">significantly</font> <font color="blue">greater than</font></font> we     expect, <font color="blue">depend upon</font> many factors, including:       ·       the extent to which <font color="blue">Angiomax </font>is <font color="blue">commercially successful</font> in the     <font color="blue">United States</font>;       ·        the  extent to which our <font color="blue">international</font> <font color="blue">distribution</font> partners,     including Nycomed, are <font color="blue">commercially successful</font>;       ·       the progress, level and timing of our research and <font color="blue">development</font>     <font color="blue">activities</font>  related  to  our <font color="blue"><font color="blue">clinical trial</font>s with respect</font> to Angiomax,     <font color="blue">clevidipine</font> and <font color="blue">cangrelor</font>;       ·       the cost and outcomes of <font color="blue">regulatory</font> submissions and reviews;       ·       <font color="blue">packaging approval</font> for Angiox from the European <font color="blue">authorities</font>, and     <font color="blue">pricing <font color="blue">reimbursement</font> approvals</font> in individual European countries, on a     <font color="blue">timely basis</font> or at all;       ·       the <font color="blue">continuation</font> or <font color="blue">termination</font> of <font color="blue">third party</font> <font color="blue">manufacturing</font> or     sales and marketing <font color="blue">arrangements</font>;       ·       the cost and <font color="blue"><font color="blue">effective</font>ness</font> of our sales and <font color="blue">marketing programs</font>;       ·       the status of <font color="blue"><font color="blue">competitive</font> products</font>;       ·       our ability to defend and enforce our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>;     and       ·       the <font color="blue">establishment</font> of <font color="blue">additional</font> strategic or licensing <font color="blue">arrangements</font>     with other companies, or <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>As of the date of this annual  report on Form 10-K, we believe, <font color="blue">based on</font> our     current operating plan, which includes anticipated <font color="blue">revenues from</font> <font color="blue">Angiomax </font>    and interest income, that our current cash, cash <font color="blue">equivalents</font> and available     for sale securities are sufficient to fund our <font color="blue">operations</font> through  at least     the next twelve months and beyond without requiring us to obtain external     financing</td>
    </tr>
    <tr>
      <td>However, if our <font color="blue">existing resources</font> are insufficient to satisfy     our <font color="blue">liquidity <font color="blue">requirements</font> due</font> to <font color="blue">slower than</font> anticipated sales of <font color="blue">Angiomax </font>    or otherwise, or if we acquire <font color="blue">additional</font> product <font color="blue">candidates</font> or <font color="blue">businesses</font>,     or if we otherwise believe that raising <font color="blue">additional</font> capital would be in our     interests and the interests of our <font color="blue">stockholders</font>, we <font color="blue">may sell equity</font> or debt     securities or seek <font color="blue">additional</font> financing through other <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Any sale     of  <font color="blue">additional</font> equity or debt securities may result in dilution to our     <font color="blue">stockholders</font>,  and  debt  financing  <font color="blue">may involve covenants limiting</font> or     restricting  our  ability  to take specific actions, such as incurring     <font color="blue">additional</font> debt or making capital <font color="blue"><font color="blue">expenditure</font>s</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that     public  or  <font color="blue">private financing will</font> be available in amounts or on terms     acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>If we seek to <font color="blue">raise funds through <font color="blue">collaboration</font></font>     or  licensing  <font color="blue">arrangements</font>  <font color="blue">with <font color="blue">third parties</font></font>, we may be required to     <font color="blue">relinquish rights</font> to products, product <font color="blue">candidates</font> or <font color="blue">technologies</font> that we     would not <font color="blue">otherwise relinquish</font> or <font color="blue">grant licenses on terms</font> that may not be     favorable to us</td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">additional</font> financing, we may be     required to delay, reduce the scope of, or <font color="blue">eliminate one</font> or more of our     planned research, <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">activities</font>, <font color="blue">which could</font>     harm our <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in our operating results could affect the price of our common     stock       Our  operating results <font color="blue">may vary from period</font> to period <font color="blue">based on</font> factors     including the amount and timing of sales of Angiomax, <font color="blue">underlying hospital</font>     demand  for  Angiomax,  our <font color="blue">wholesalers</font>’ <font color="blue">buying patterns</font>, including in     <font color="blue">connection</font>  with our <font color="blue">restructured</font> wholesaler <font color="blue">arrangements</font>, the timing,     expenses and results of <font color="blue">clinical trial</font>s, <font color="blue">announcements</font> regarding clinical     trial  results and <font color="blue">product introductions by us</font> or our <font color="blue">competitors</font>, the     <font color="blue">availability</font> and timing of third-party <font color="blue">reimbursement</font>, including in Europe,     sales and <font color="blue">marketing expenses</font> and the timing of <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>If our     operating results do not meet the <font color="blue">expectations</font> of <font color="blue">securities analysts</font> and     <font color="blue">investors as</font> a result of these or other factors, the <font color="blue">trading price</font> of our     <font color="blue">common stock</font> <font color="blue">will likely</font> decrease</td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font>     may make it <font color="blue">difficult</font> for you to <font color="blue">sell <font color="blue">common stock</font></font> when you want or at     <font color="blue">attractive prices</font>       Our <font color="blue">common stock</font> has been and in the <font color="blue">future may</font> be subject to substantial     price <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td><font color="blue">From January </font>1, 2004 to <font color="blue">December </font>31, 2005, the closing     price of our <font color="blue">common stock</font> ranged from a high of dlra35dtta11       24     ______________________________________________________________________       per share to a low of dlra15dtta92 per share</td>
    </tr>
    <tr>
      <td>The value of your <font color="blue">investment</font> could     <font color="blue">decline due</font> to the effect of any of the <font color="blue">following factors upon</font> the market     price of our <font color="blue">common stock</font>:       ·        changes  in  securities  analysts’ estimates of our financial     performance;       ·       changes in <font color="blue">valuations</font> of similar companies;       ·       <font color="blue">variations</font> in our quarterly operating results;       ·       <font color="blue">acquisition</font>s and <font color="blue">strategic partnerships</font>;       ·        <font color="blue">announcements</font>  of <font color="blue">technological innovations</font> or <font color="blue">new commercial</font>     products by us or our <font color="blue">competitors</font>;       ·       <font color="blue">disclosure</font> of results of <font color="blue">clinical testing</font> or <font color="blue">regulatory</font> <font color="blue">proceedings</font>     by us or our <font color="blue">competitors</font>;       ·       the timing, amount and receipt of <font color="blue">revenue from sales</font> of our products     and <font color="blue">margins on sales</font> of our products;       ·       <font color="blue">governmental regulation</font> and approvals;       ·       <font color="blue">development</font>s in <font color="blue">patent rights</font> or other <font color="blue"><font color="blue">proprietary</font> rights</font>;       ·       changes in our <font color="blue">management</font>; and       ·       <font color="blue">general market conditions</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> has experienced <font color="blue">significant price</font> and volume     <font color="blue">fluctuations</font>, and the <font color="blue">market price</font>s of <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font> have been     <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">broad market</font> and industry <font color="blue">fluctuations</font> that are     not within our <font color="blue">control may <font color="blue">adversely affect</font></font> the <font color="blue">trading price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>You must be willing to bear the risk of <font color="blue">fluctuations</font> in the price of     our <font color="blue">common stock</font> and the risk that the value of your <font color="blue">investment</font> in our     <font color="blue">securities could decline</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to Commercialization       <font color="blue">Angiomax </font><font color="blue">may compete with</font> all <font color="blue">categories</font> of <font color="blue"><font color="blue">anticoagulant</font> drug</font>s, which may     limit the use of <font color="blue">Angiomax </font>      Because each category of <font color="blue"><font color="blue">anticoagulant</font> drug</font> acts <font color="blue">on different components</font> of     the <font color="blue">clotting process</font>, we believe that <font color="blue">there will</font> be <font color="blue">continued clinical</font> work     to determine the <font color="blue">best <font color="blue">combination</font></font> of drugs for <font color="blue">clinical use</font></td>
    </tr>
    <tr>
      <td>We recognize     that <font color="blue">Angiomax </font><font color="blue">may compete with</font> other <font color="blue"><font color="blue">anticoagulant</font> drug</font>s to the extent     <font color="blue">Angiomax </font>and any of these <font color="blue"><font color="blue">anticoagulant</font> drug</font>s are approved for the same     <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>In  addition,  other <font color="blue"><font color="blue">anticoagulant</font> drug</font>s <font color="blue">may compete with</font> <font color="blue">Angiomax </font>for     hospital financial resources</td>
    </tr>
    <tr>
      <td>For example, many US hospitals receive a     fixed <font color="blue"><font color="blue">reimbursement</font> amount per procedure</font> for the <font color="blue">angioplasties</font> and other     <font color="blue">treatment therapies</font> they perform</td>
    </tr>
    <tr>
      <td>Because this amount is not <font color="blue">based on</font> the     <font color="blue">actual expenses</font> the hospital incurs, hospitals may choose to use either     <font color="blue">Angiomax </font>or other <font color="blue"><font color="blue">anticoagulant</font> drug</font>s, but not <font color="blue">necessarily several</font> of the     <font color="blue">drugs together</font></td>
    </tr>
    <tr>
      <td>Because the market for thrombin <font color="blue">inhibitors</font> is <font color="blue">competitive</font>, our product may     not obtain widespread use       We have positioned <font color="blue">Angiomax </font>as a <font color="blue">replacement</font> for heparin, which is a widely     used, <font color="blue">inexpensive</font>, generic drug used in <font color="blue"><font color="blue">patients with</font> arterial thrombosis</font></td>
    </tr>
    <tr>
      <td>Because heparin is <font color="blue">inexpensive</font> and has been widely used for many years,     physicians and medical decision-makers may be hesitant to adopt Angiomax</td>
    </tr>
    <tr>
      <td>In     addition, due to the <font color="blue">high incidence</font> and severity of <font color="blue">cardiovascular diseases</font>,     <font color="blue">competition</font> in the market for thrombin <font color="blue">inhibitors</font> is intense and growing</td>
    </tr>
    <tr>
      <td>The rate of <font color="blue">Angiomax </font><font color="blue">sales growth</font> was <font color="blue">slower than</font> we expected in 2005, and     we <font color="blue">cannot assure</font> you that our <font color="blue">increased sales</font> and <font color="blue">marketing efforts</font> or     <font color="blue">expanded label will</font> result in <font color="blue">higher revenues</font> or income</td>
    </tr>
    <tr>
      <td>There are a number     of direct and indirect thrombin <font color="blue">inhibitors</font> currently on the market, awaiting     <font color="blue">regulatory</font>  approval and in <font color="blue">development</font>, including <font color="blue">orally <font color="blue">administered</font></font>     agents</td>
    </tr>
    <tr>
      <td>The thrombin <font color="blue">inhibitors</font> on the market include products for use in     the treatment of <font color="blue">patients with</font> HIT/HITTS, <font color="blue">patients with</font> unstable angina and     <font color="blue">patients with</font> deep vein thrombosis</td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________       We face substantial <font color="blue">competition</font>, which may result in <font color="blue">others discovering</font>,     developing or <font color="blue"><font color="blue">commercializing</font> competing products</font> before or more <font color="blue">successfully</font>     than we do       Our industry is highly <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend on</font> our ability     to acquire and develop products and <font color="blue">apply <font color="blue">technology</font></font>, and our ability to     establish and maintain markets for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">competitors</font> in     the <font color="blue"><font color="blue">United States</font> </font>and other countries include <font color="blue">major <font color="blue">pharmaceutical</font></font> and     chemical companies, specialized <font color="blue">pharmaceutical</font> companies and <font color="blue">bio<font color="blue">technology</font></font>     firms, universities and other <font color="blue">research institutions</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font>     have  <font color="blue">substantially</font>  greater research and <font color="blue">development</font> <font color="blue">capabilities</font> and     experience, and greater <font color="blue">manufacturing</font>, marketing and financial resources,     than we do</td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">competitors</font> may develop or <font color="blue">license products</font> or     other novel <font color="blue">technologies</font> that are more <font color="blue">effective</font>, safer, more <font color="blue">convenient</font> or     less  costly  than  existing  products  or <font color="blue">technologies</font> or products or     <font color="blue">technologies</font>  that  are being developed by us or may obtain <font color="blue">regulatory</font>     approvals  for  products  more <font color="blue">rapidly than</font> we are able</td>
    </tr>
    <tr>
      <td><font color="blue">Technological     </font><font color="blue">development</font>  by  others  may render our products or product <font color="blue">candidates</font>     non<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We may not be successful in <font color="blue">establishing</font> or maintaining     technological <font color="blue">competitive</font>ness</td>
    </tr>
    <tr>
      <td>Near-term  growth  in  our sales of <font color="blue">Angiomax </font>is <font color="blue"><font color="blue">dependent</font> on</font> continued     <font color="blue">physician acceptance</font> of <font color="blue">Angiomax </font><font color="blue">clinical data</font>       In the fall of 2002, we completed a 6cmam002 patient post-marketing Phase 3b/4     <font color="blue">clinical trial</font> of <font color="blue">Angiomax </font>in coronary <font color="blue">angioplasty</font> called REPLACE-2</td>
    </tr>
    <tr>
      <td>In     November 2002, the <font color="blue">principal investigators</font> of the REPLACE-2 trial announced     that, <font color="blue">based on</font> 30-day patient follow-up results, <font color="blue">Angiomax </font>met all of the     primary and <font color="blue">secondary <font color="blue">objectives</font></font> of the trial</td>
    </tr>
    <tr>
      <td>In March 2003, we released     the results of the <font color="blue">detailed cost analysis study</font> to examine per-patient total     hospital  resource  <font color="blue">consumption</font>  at  US  clinical  trial  sites</td>
    </tr>
    <tr>
      <td>In     September 2003, the <font color="blue">principal investigators</font> of the <font color="blue">clinical trial</font> announced     that, <font color="blue">based on</font> six-month patient follow-up results, <font color="blue">Angiomax </font><font color="blue">again met</font> all     of the primary and <font color="blue">secondary <font color="blue">objectives</font></font> of the trial</td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2003, the     <font color="blue">principal investigators</font> presented one-year follow-up mortality data from the     trial, which confirmed the 30-day and six-month mortality results</td>
    </tr>
    <tr>
      <td>In March 2006, the <font color="blue">principal investigators</font> of the ACUITY trial announced the     results of this trial <font color="blue">based on</font> 30-day patient results</td>
    </tr>
    <tr>
      <td>We believe that the near-term <font color="blue">commercial success</font> of <font color="blue">Angiomax </font>will depend     upon the extent to which physicians, patients and other key decision-makers     accept the results of the <font color="blue">Angiomax </font><font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>For example, since the     original results of REPLACE-2 were announced, <font color="blue">additional</font> hospitals have     granted <font color="blue">Angiomax </font>formulary approval and <font color="blue">hospital demand</font> for the product has     increased</td>
    </tr>
    <tr>
      <td>We cannot be certain, however, that these <font color="blue">trends will continue</font></td>
    </tr>
    <tr>
      <td>Some <font color="blue">commentators</font> have <font color="blue">challenged various aspects</font> of the <font color="blue">trial design</font> of     REPLACE-2, the conduct of the study and the analysis and <font color="blue">interpretation</font> of     the  results  from the study, including how we <font color="blue">define bleeding</font> and the     <font color="blue">clinical relevance</font> of types of <font color="blue">ischemic events</font></td>
    </tr>
    <tr>
      <td>The FDA has noted that in     its view, statistical non-inferiority was not <font color="blue"><font color="blue">demonstrate</font>d</font> for the 30-day     <font color="blue">ischemic endpoint</font> in the REPLACE-2 trial</td>
    </tr>
    <tr>
      <td>Similarly, we cannot be certain of     the extent to which physicians, patients and other key decision-makers will     accept the results of the ACUITY trial</td>
    </tr>
    <tr>
      <td>If physicians, patients and other     key decision-makers do not accept the REPLACE-2 and ACUITY trial results,     adoption  of  <font color="blue">Angiomax </font>may suffer, and our business will be <font color="blue">materially</font>     <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       Our ability to <font color="blue">generate future revenue from products will</font> be <font color="blue">affected by</font>     <font color="blue">reimbursement</font> and <font color="blue">drug pricing</font>       <font color="blue">Acceptable  </font>levels  of  <font color="blue">reimbursement</font> of <font color="blue">drug <font color="blue">treatments</font> by government</font>     <font color="blue">authorities</font>, private health insurers and other <font color="blue">organizations will</font> have an     effect  on  our  ability  to  <font color="blue">successfully</font>  <font color="blue">commercialize</font>, and attract     <font color="blue">collaborative partners</font> to invest in the <font color="blue">development</font> of, product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We cannot be sure that <font color="blue">reimbursement</font> in the <font color="blue"><font color="blue">United States</font> </font>or elsewhere will     be available for any products we may develop or, if already available, will     not be decreased in the future</td>
    </tr>
    <tr>
      <td>If <font color="blue">reimbursement</font> is not available or is     <font color="blue"><font color="blue">available on</font>ly</font> to limited levels, we may not be able to <font color="blue">commercialize</font> our     products, or may not be able to obtain a satisfactory <font color="blue">financial return on</font>     our products</td>
    </tr>
    <tr>
      <td>In certain countries, <font color="blue">particularly</font> the countries of the European Union, the     pricing of <font color="blue">prescription</font> <font color="blue"><font color="blue">pharmaceutical</font>s</font> and the level of <font color="blue">reimbursement</font> are     subject to <font color="blue">governmental control</font></td>
    </tr>
    <tr>
      <td>In some countries, it can take an extended     period of time to establish and obtain <font color="blue">reimbursement</font>, and <font color="blue">reimbursement</font>     <font color="blue">approval may</font> be required at the individual patient level, which can lead to     <font color="blue">further delays</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">payers increasingly</font> are <font color="blue">challenging prices charged</font> for medical     products and services</td>
    </tr>
    <tr>
      <td>Also, the trend toward managed health care in the     <font color="blue"><font color="blue">United States</font> </font>and the changes in health insurance programs, as well as     <font color="blue">legislative</font>  proposals,  may result in <font color="blue">lower prices</font> for <font color="blue">pharmaceutical</font>     products, including any products that may be <font color="blue">offered by us</font></td>
    </tr>
    <tr>
      <td>Cost-cutting     measures that <font color="blue">health care providers</font> are <font color="blue">instituting</font>, and the effect of any     health care reform, could <font color="blue">materially</font> <font color="blue">adversely affect</font> our ability to sell     any  products  that  are  <font color="blue">successfully</font> developed by us and <font color="blue">approved by</font>     <font color="blue">regulators</font></td>
    </tr>
    <tr>
      <td>Moreover, we are unable to predict what <font color="blue">additional</font> <font color="blue">legislation</font>     or regulation, if any, relating to the <font color="blue">health care industry</font> or third-party     coverage and <font color="blue">reimbursement</font> may be enacted in the future or what effect such     <font color="blue">legislation</font> or <font color="blue">regulation would</font> have on our business</td>
    </tr>
    <tr>
      <td>We could be exposed to <font color="blue">significant <font color="blue">liability</font></font> claims if we are unable to     obtain  <font color="blue">insurance at</font> acceptable costs and <font color="blue">adequate levels</font> or otherwise     <font color="blue">protect ourselves against potential product <font color="blue">liability</font></font> claims       Our business <font color="blue">exposes us</font> to <font color="blue">potential product <font color="blue">liability</font> risks which</font> are     inherent  in  the  testing, <font color="blue">manufacturing</font>, marketing and sale of human     <font color="blue">healthcare products</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims might be made <font color="blue">by patients</font> in     clinical  trials,  consumers,  <font color="blue">health care providers</font> or <font color="blue">pharmaceutical</font>     companies or others that sell our products</td>
    </tr>
    <tr>
      <td>These claims may be made even     with  respect  to those products that are <font color="blue"><font color="blue">manufacture</font>d</font> in licensed and     <font color="blue">regulated <font color="blue">facilities</font></font> or otherwise possess <font color="blue">regulatory</font> approval for commercial     sale</td>
    </tr>
    <tr>
      <td>These claims <font color="blue">could expose us</font> to <font color="blue">significant liabilities</font> that <font color="blue">could prevent</font>     or <font color="blue">interfere with</font> the <font color="blue">development</font> or <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims could require us to <font color="blue">spend significant</font> time and     money in <font color="blue">litigation</font> or <font color="blue">pay significant damages</font></td>
    </tr>
    <tr>
      <td>As of the date of this     annual report on Form 10-K, we are covered, with respect to our commercial     sales and our <font color="blue">clinical trial</font>s, by products <font color="blue">liability</font> insurance in the amount     of dlra20dtta0 million per occurrence and dlra20dtta0 million annually in the aggregate     on a claims-made basis</td>
    </tr>
    <tr>
      <td>This coverage may not be adequate to cover any     product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>As  we <font color="blue">commercialize</font> our products, we may wish to increase our product     <font color="blue">liability</font> insurance</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> coverage is expensive</td>
    </tr>
    <tr>
      <td>In the future,     we may not be able to maintain or obtain <font color="blue">such product</font> <font color="blue">liability</font> insurance on     <font color="blue">reasonable terms</font>, at a reasonable cost or in <font color="blue">sufficient amounts</font> to protect     <font color="blue">us against losses due</font> to product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to <font color="blue">Regulatory </font>Approval of Our Product Candidates       If we do not obtain <font color="blue">regulatory</font> approvals for our product <font color="blue">candidates</font> we will     not be able to market our product <font color="blue">candidates</font> and our ability to generate     <font color="blue">additional</font> revenues could be <font color="blue">materially</font> impaired       Except for Angiomax, which has been approved for sale in the <font color="blue"><font color="blue">United States</font> </font>    for use as an <font color="blue">anticoagulant</font> in <font color="blue">combination</font> with aspirin in <font color="blue">patients with</font>     unstable angina undergoing <font color="blue">percutaneous</font> coronary <font color="blue">interventions</font>, and which     has been approved for sale in the <font color="blue">European Union </font>and in other countries for     <font color="blue"><font color="blue">indication</font>s</font> similar to those <font color="blue">approved by</font> the FDA, we do not have a product     approved for       27     ______________________________________________________________________       sale in the <font color="blue"><font color="blue">United States</font> </font>or any <font color="blue">foreign market</font></td>
    </tr>
    <tr>
      <td>We must obtain approval     from the FDA in order to sell our product <font color="blue">candidates</font> in the <font color="blue"><font color="blue">United States</font> </font>    and  from  foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> in order to sell our product     <font color="blue">candidates</font> in other countries</td>
    </tr>
    <tr>
      <td>Securing <font color="blue">regulatory</font> approval requires the     submission of extensive pre-clinical and <font color="blue">clinical data</font>, information about     product <font color="blue">manufacturing</font> processes and inspection of <font color="blue">facilities</font> and supporting     information to the <font color="blue">regulatory</font> <font color="blue">authorities</font> for each therapeutic <font color="blue">indication</font> to     establish the product’s safety and efficacy</td>
    </tr>
    <tr>
      <td>We must <font color="blue">successfully</font> complete     our <font color="blue">clinical trial</font>s and <font color="blue">demonstrate</font> <font color="blue">manufacturing</font> capability before we can     file for approval to sell our products</td>
    </tr>
    <tr>
      <td>Delays in obtaining or failure to     obtain <font color="blue">regulatory</font> approvals may:       ·       delay or prevent the successful <font color="blue">commercialization</font> of any of our     product <font color="blue">candidates</font>;       ·       diminish our <font color="blue">competitive</font> advantage; and       ·       defer or decrease our receipt of revenues</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> review and <font color="blue">approval process</font> to obtain <font color="blue">marketing approval</font> for     a new drug takes many years and requires the <font color="blue">expenditure</font> of substantial     resources</td>
    </tr>
    <tr>
      <td>This  process  can  vary  <font color="blue">substantially</font> <font color="blue">based on</font> the type,     <font color="blue">complexity</font>,  novelty and <font color="blue">indication</font> of the <font color="blue"><font color="blue">product candidate</font> involved</font></td>
    </tr>
    <tr>
      <td>Changes in the <font color="blue">regulatory</font> approval policy during the <font color="blue">development</font> period,     changes  in or the <font color="blue">enactment</font> of <font color="blue">additional</font> statutes or <font color="blue">regulations</font>, or     changes in <font color="blue">regulatory</font> review for <font color="blue">each submitted product <font color="blue">application</font> may</font>     cause delays in the approval or rejection of an <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font>     <font color="blue">authorities</font> have substantial <font color="blue">discretion</font> in the <font color="blue">approval process</font> and may     refuse to accept any <font color="blue">application</font> or may decide that data is insufficient for     approval and require <font color="blue">additional</font> pre-clinical, clinical or other studies</td>
    </tr>
    <tr>
      <td>In     addition, varying <font color="blue">interpretation</font>s of the data obtained from pre-clinical and     <font color="blue">clinical testing</font> <font color="blue">could delay</font>, limit or prevent <font color="blue">regulatory</font> approval of a     <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot expand</font> the <font color="blue"><font color="blue">indication</font>s</font> for which we are marketing <font color="blue">Angiomax </font>unless     we receive FDA approval for each <font color="blue">additional</font> <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>Failure to expand     these <font color="blue"><font color="blue">indication</font>s</font> will limit the size of the <font color="blue">commercial market</font> for <font color="blue">Angiomax </font>      The FDA has approved <font color="blue">Angiomax </font>for use as an <font color="blue">anticoagulant</font> in <font color="blue">combination</font>     with  aspirin in <font color="blue">patients with</font> unstable angina undergoing <font color="blue">percutaneous</font>     coronary  <font color="blue">interventions</font></td>
    </tr>
    <tr>
      <td>One  of  our key <font color="blue">objectives</font> is to expand the     <font color="blue"><font color="blue">indication</font>s</font> for which <font color="blue">Angiomax </font>is approved for marketing by the FDA In     order to market <font color="blue">Angiomax </font>for these expanded <font color="blue"><font color="blue">indication</font>s</font>, we will need to     conduct <font color="blue">appropriate</font> <font color="blue">clinical trial</font>s, obtain positive results from those     trials and obtain FDA approval for such proposed <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>If we are     <font color="blue">unsuccessful</font> in expanding the approved <font color="blue"><font color="blue">indication</font>s</font> for the use of Angiomax,     the size of the <font color="blue">commercial market</font> for <font color="blue">Angiomax </font>will be limited</td>
    </tr>
    <tr>
      <td>Clinical trials of product <font color="blue">candidates</font> are expensive and time-consuming, and     the results of these trials are uncertain       Before  we can obtain <font color="blue">regulatory</font> approvals to market any product for a     particular <font color="blue">indication</font>, we will be required to complete pre-clinical studies     and  extensive <font color="blue">clinical trial</font>s in humans to <font color="blue">demonstrate</font> the safety and     efficacy of <font color="blue">such product</font> for such <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>Clinical testing is expensive, <font color="blue">difficult</font> to design and implement, can take     many  years  to  complete  and  is <font color="blue">uncertain as</font> to outcome</td>
    </tr>
    <tr>
      <td>Success in     pre-<font color="blue">clinical testing</font> or early <font color="blue">clinical trial</font>s does not ensure that later     <font color="blue">clinical trial</font>s will be successful, and interim results of a <font color="blue">clinical trial</font>     do not <font color="blue">necessarily predict final</font> results</td>
    </tr>
    <tr>
      <td>An unexpected result in one or     more  of our <font color="blue">clinical trial</font>s can occur at any stage of testing</td>
    </tr>
    <tr>
      <td>We may     experience  numerous  <font color="blue">unforeseen events during</font>, or as a result of, the     clinical  trial  process that <font color="blue">could delay</font> or <font color="blue">prevent us from</font> receiving     <font color="blue">regulatory</font> approval or <font color="blue">commercializing</font> our products, including:       ·       our <font color="blue">clinical trial</font>s may produce negative or <font color="blue">inconclusive</font> results,     and we may decide, or <font color="blue">regulators</font> may require us, to conduct <font color="blue">additional</font>     <font color="blue">clinical trial</font>s;       28     ______________________________________________________________________       ·       data obtained from pre-<font color="blue">clinical testing</font> and <font color="blue">clinical trial</font>s may be     subject to varying <font color="blue">interpretation</font>s, <font color="blue">which could</font> result in the FDA or other     <font color="blue">regulatory</font>  <font color="blue">authorities</font>  deciding not to approve a product in a timely     fashion, or at all;       ·        the  cost of <font color="blue">clinical trial</font>s may be <font color="blue">greater than</font> we currently     anticipate;       ·       any <font color="blue">regulatory</font> approval we ultimately obtain may be limited or     subject to <font color="blue">restrictions</font> or post-approval <font color="blue">commitment</font>s that render the product     commercially non-viable;       ·       <font color="blue">regulators</font> or <font color="blue">institutional review boards may</font> not <font color="blue">authorize us</font> to     commence a <font color="blue">clinical trial</font> or conduct a <font color="blue">clinical trial</font> at a <font color="blue">prospective trial</font>     site;       ·       we, or the FDA, <font color="blue">might suspend</font> or terminate a <font color="blue">clinical trial</font> at any     time <font color="blue">on various grounds</font>, including a finding that <font color="blue">participating patients</font> are     being exposed to unacceptable <font color="blue">health risks</font>; and       ·       the effects of our product <font color="blue">candidates</font> may not be the desired effects     or may include undesirable side effects or the product <font color="blue">candidates</font> may have     other <font color="blue">unexpected characteristics</font></td>
    </tr>
    <tr>
      <td>The rate of <font color="blue">completion</font> of <font color="blue">clinical trial</font>s depends in part upon the rate of     <font color="blue">enrollment</font> of patients</td>
    </tr>
    <tr>
      <td>Patient <font color="blue">enrollment</font> is a function of many factors,     including the size of the <font color="blue">patient population</font>, the proximity of patients to     clinical sites, the <font color="blue">eligibility criteria</font> for the trial, the existence of     competing  clinical  trials and the <font color="blue">availability</font> of <font color="blue">alternative</font> or new     <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>In particular, the <font color="blue">patient population</font> targeted by some of our     <font color="blue">clinical trial</font>s may be small</td>
    </tr>
    <tr>
      <td>Delays in patient <font color="blue">enrollment</font> in any of our     current or future <font color="blue">clinical trial</font>s may result in <font color="blue">increased costs</font> and program     delays</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> the extensive <font color="blue">regulatory</font> <font color="blue">requirements</font> to which we,     our <font color="blue">contract <font color="blue">manufacture</font>rs</font> and our <font color="blue">products could</font> be subject to <font color="blue">restrictions</font>     or <font color="blue">withdrawal from</font> the market and we could be subject to penalties       The testing, <font color="blue">manufacturing</font>, labeling, advertising, promotion, export, and     marketing,  among other things, of our products, both before and after     approval, are subject to extensive regulation by governmental <font color="blue">authorities</font> in     the <font color="blue">United States</font>, Europe and elsewhere <font color="blue">throughout</font> the world</td>
    </tr>
    <tr>
      <td>Our failure or     the  failure  of  our  <font color="blue">contract <font color="blue">manufacture</font>rs</font>  to <font color="blue">comply with</font> the laws     <font color="blue">administered</font>  by  the  FDA,  the  European  Medicines Agency, or other     governmental <font color="blue">authorities</font> could result in any of the following:       ·       delay in approving or refusal to approve a product;       ·       <font color="blue">product recall</font> or seizure;       ·       <font color="blue">interruption</font> of production;       ·       operating <font color="blue">restrictions</font>;       ·       <font color="blue">warning letters</font>;       ·       <font color="blue">injunctions</font>;       ·       <font color="blue">criminal <font color="blue">prosecutions</font></font>; and       ·       unanticipated <font color="blue"><font color="blue">expenditure</font>s</font></td>
    </tr>
    <tr>
      <td>Both  before  and  after  approval  of  a product, <font color="blue">quality control</font> and     <font color="blue">manufacturing</font> procedures must conform to cGMP <font color="blue">Regulatory </font><font color="blue">authorities</font>,     including the FDA, <font color="blue">periodically</font> inspect <font color="blue">manufacturing</font> <font color="blue">facilities</font> to assess     compliance with GMP Accordingly, we and our <font color="blue">contract <font color="blue">manufacture</font>rs</font> will     need  to  continue  to  expend time, monies, and effort in the area of     production and <font color="blue">quality control</font> to maintain GMP compliance</td>
    </tr>
    <tr>
      <td>29     ______________________________________________________________________       <font color="blue">Risks Related </font>to our <font color="blue">Dependence </font>on Third Parties for Manufacturing, Research     and Development and Distribution Activities       We <font color="blue">depend on single suppliers</font> for the production of Angiomax, <font color="blue">clevidipine</font>     and <font color="blue">cangrelor</font> bulk drug substance and <font color="blue"><font color="blue">different single supplier</font>s</font> to carry     out all fill-finish <font color="blue">activities</font>       We do not <font color="blue">manufacture</font> any of our products and do not plan to develop any     <font color="blue">capacity</font>  to <font color="blue">manufacture</font> them</td>
    </tr>
    <tr>
      <td>As of the date of this annual report on     Form 10-K,  we obtain all of our <font color="blue">Angiomax </font>bulk drug substance from one     <font color="blue">manufacture</font>r, UCB Bioproducts, and rely on another <font color="blue">manufacture</font>r, Ben Venue     Laboratories, to carry out all fill-finish <font color="blue">activities</font> for Angiomax, which     includes <font color="blue">final formulation</font> and transfer of the <font color="blue">drug into vials</font> where it is     then  freeze-dried  and  sealed</td>
    </tr>
    <tr>
      <td>The  terms of our <font color="blue"><font color="blue">agreement</font> with</font> UCB     Bioproducts  require us to <font color="blue">purchase from</font> UCB Bioproducts a substantial     portion of our <font color="blue">Angiomax </font>bulk drug product <font color="blue"><font color="blue">manufacture</font>d</font> using the Chemilog     process</td>
    </tr>
    <tr>
      <td>As of the date of this annual report on Form 10-K, we obtain all of our     <font color="blue">clevidipine</font> bulk drug substance from one <font color="blue">manufacture</font>r, Johnson Matthey     Pharma Services</td>
    </tr>
    <tr>
      <td>We rely on a <font color="blue">different single supplier</font>, Hospira, Inc, and     its <font color="blue">proprietary</font> formulation <font color="blue">technology</font>, for the <font color="blue">manufacture</font> of all finished     <font color="blue">clevidipine</font> product, as well as for <font color="blue">release testing</font> and <font color="blue">clinical packaging</font></td>
    </tr>
    <tr>
      <td>We have transferred the <font color="blue">manufacturing</font> process for all of our <font color="blue">cangrelor</font> bulk     drug substance from <font color="blue">AstraZeneca to Johnson Matthey Pharma Services </font>for scale     up and <font color="blue">manufacture</font> <font color="blue">for <font color="blue">Phase III </font></font><font color="blue">clinical trial</font>s and <font color="blue">commercial supplies</font></td>
    </tr>
    <tr>
      <td>We     will  also  rely on a <font color="blue">different single supplier</font>, Baxter Pharmaceutical     Solutions LLC, for the <font color="blue">manufacture</font> of all finished <font color="blue">cangrelor</font> drug product     for all <font color="blue">Phase III </font><font color="blue">clinical trial</font>s and to carry out <font color="blue">release testing</font></td>
    </tr>
    <tr>
      <td>There  are  a limited number of <font color="blue">manufacture</font>rs capable of <font color="blue">manufacturing</font>     Angiomax, <font color="blue">clevidipine</font> and <font color="blue">cangrelor</font></td>
    </tr>
    <tr>
      <td>As of the date of this annual report on     Form 10-K, we do not have <font color="blue">alternative</font> sources for production of bulk drug     substance or to carry out fill-finish <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Consolidation </font>within the     <font color="blue">pharmaceutical</font> <font color="blue">manufacturing</font> industry could further reduce the number of     <font color="blue">manufacture</font>rs capable of producing our products, or <font color="blue">otherwise affect</font> our     <font color="blue">existing contractual relationships</font></td>
    </tr>
    <tr>
      <td>announced that it acquired the bioproducts <font color="blue">manufacturing</font> division of UCB,     our sole source of <font color="blue">Angiomax </font><font color="blue">bulk drug product as</font> of the date of this annual     report</td>
    </tr>
    <tr>
      <td>In July 2004, we had <font color="blue">entered into</font> a <font color="blue">development</font> and <font color="blue">supply <font color="blue">agreement</font></font>     with Lonza for the <font color="blue">development</font> of an <font color="blue">alternative</font> method of <font color="blue">manufacture</font> and     <font color="blue">commercial supply</font> of Angiomax</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>the <font color="blue">acquisition</font>, we will rely on     Lonza for both a continuing <font color="blue">commercial supply</font> of <font color="blue">Angiomax </font>and <font color="blue">development</font> of     the <font color="blue">alternative</font> method of <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>In the event that UCB Bioproducts,     Lonza, Johnson Matthey, Hospira, Ben Venue or Baxter is unable to carry out     their respective <font color="blue">manufacturing</font> <font color="blue">obligations</font>, we may be unable to obtain     <font color="blue">alternative</font> <font color="blue">manufacturing</font>, or obtain such <font color="blue">manufacturing</font> on commercially     <font color="blue">reasonable terms</font> or on a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>If we were required to transfer     <font color="blue">manufacturing</font> processes to other <font color="blue">third party</font> <font color="blue">manufacture</font>rs, we would be     required to satisfy various <font color="blue">regulatory</font> <font color="blue">requirements</font>, <font color="blue">which could</font> cause us to     experience <font color="blue">significant delays</font> in receiving an <font color="blue">adequate supply</font> of Angiomax,     <font color="blue">clevidipine</font>  or <font color="blue">cangrelor</font></td>
    </tr>
    <tr>
      <td>Any delays in the <font color="blue">manufacturing</font> process may     <font color="blue">adversely impact</font> our ability to <font color="blue">meet commercial demands</font> for <font color="blue">Angiomax </font>on a     <font color="blue">timely basis</font> and <font color="blue">supply product</font> for <font color="blue">clinical trial</font>s of Angiomax, <font color="blue">clevidipine</font>     or <font color="blue">cangrelor</font></td>
    </tr>
    <tr>
      <td>30     ______________________________________________________________________       The <font color="blue">development</font> and <font color="blue">commercialization</font> of our products may be terminated or     delayed, and the costs of <font color="blue">development</font> and <font color="blue">commercialization</font> may increase, if     <font color="blue"><font color="blue">third parties</font> on whom</font> we rely to <font color="blue">manufacture</font> and support the <font color="blue">development</font> and     <font color="blue">commercialization</font> of our products do not fulfill their <font color="blue">obligations</font>       Our  <font color="blue">development</font>  and <font color="blue">commercialization</font> strategy entails entering into     <font color="blue">arrangements</font> with corporate and academic <font color="blue">collaborators</font>, contract research     organizations, <font color="blue">distributors</font>, third-party <font color="blue">manufacture</font>rs, <font color="blue">licensors</font>, licensees     and others to conduct <font color="blue">development</font> work, manage or conduct our clinical     trials, <font color="blue">manufacture</font> our products and market and sell our <font color="blue">products outside</font> of     the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We do not have the expertise or the resources to conduct     such <font color="blue">activities</font> on our own and, as a result, are <font color="blue">particularly</font> <font color="blue"><font color="blue">dependent</font> on</font>     <font color="blue">third parties</font> in most areas</td>
    </tr>
    <tr>
      <td>We may not be able to maintain our existing <font color="blue">arrangements</font> with respect to the     <font color="blue">commercialization</font> or <font color="blue">manufacture</font> of <font color="blue">Angiomax </font>or establish and maintain     <font color="blue">arrangements</font> to develop and <font color="blue">commercialize</font> <font color="blue">clevidipine</font>, <font color="blue">cangrelor</font> or any     <font color="blue">additional</font> product <font color="blue">candidates</font> or products we may acquire on terms that are     acceptable to us</td>
    </tr>
    <tr>
      <td>Any current or future <font color="blue">arrangements</font> for <font color="blue">development</font> and     <font color="blue">commercialization</font> may not be successful</td>
    </tr>
    <tr>
      <td>If we are not able to establish or     maintain <font color="blue"><font color="blue">agreement</font>s</font> relating to Angiomax, <font color="blue">clevidipine</font>, <font color="blue">cangrelor</font> or any     <font color="blue">additional</font> products we may acquire on terms that we deem favorable, our     results of <font color="blue">operations</font> would be <font color="blue"><font color="blue">materially</font> <font color="blue"><font color="blue">adversely affect</font>ed</font></font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> not perform their <font color="blue">obligations</font> as expected</td>
    </tr>
    <tr>
      <td>The amount and     timing of resources that <font color="blue">third parties</font> devote to developing, <font color="blue">manufacturing</font>     and  <font color="blue">commercializing</font>  our  products  are  not  within our control</td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">collaborators</font> may</font> develop, <font color="blue">manufacture</font> or <font color="blue">commercialize</font>, either alone or     with others, products and services that are similar to or <font color="blue">competitive</font> with     the products that are the subject of the <font color="blue"><font color="blue">collaboration</font> with us</font></td>
    </tr>
    <tr>
      <td>Furthermore,     our <font color="blue">interests may differ from</font> those of <font color="blue">third parties</font> that <font color="blue">manufacture</font> or     <font color="blue">commercialize</font>  our  products</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">collaborators</font> may</font> re-evaluate their     priorities   from  time  to  time,  including  following  mergers  and     <font color="blue">consolidations</font>, and change the focus of their <font color="blue">development</font>, <font color="blue">manufacturing</font> or     <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>Dis<font color="blue"><font color="blue">agreement</font>s</font> that may arise with these third     parties  could  delay or lead to the <font color="blue">termination</font> of the <font color="blue">development</font> or     <font color="blue">commercialization</font> of our product <font color="blue">candidates</font>, or result in <font color="blue">litigation</font> or     arbitration, which would be time consuming and expensive</td>
    </tr>
    <tr>
      <td>If  any  third  party that <font color="blue">manufacture</font>s or supports the <font color="blue">development</font> or     <font color="blue">commercialization</font> of our products breaches or terminates its <font color="blue"><font color="blue">agreement</font> with</font>     us, or fails to commit sufficient resources to our <font color="blue">collaboration</font> or conduct     its  <font color="blue">activities</font> in a <font color="blue">timely manner</font>, or fails to <font color="blue">comply with</font> <font color="blue">regulatory</font>     <font color="blue">requirements</font>, such breach, <font color="blue">termination</font> or <font color="blue">failure could</font>:       ·       delay or otherwise <font color="blue">adversely impact</font> the <font color="blue">manufacturing</font>, <font color="blue">development</font>     or <font color="blue">commercialization</font> of Angiomax, <font color="blue">clevidipine</font>, <font color="blue">cangrelor</font> or any <font color="blue">additional</font>     products that we may acquire or develop;       ·        require us to seek a <font color="blue">new collaborator</font> or undertake unforeseen     <font color="blue">additional</font> responsibilities or devote unforeseen <font color="blue">additional</font> resources to the     <font color="blue">manufacturing</font>, <font color="blue">development</font> or <font color="blue">commercialization</font> of our products; or       ·       result in the <font color="blue">termination</font> of the <font color="blue">development</font> or <font color="blue">commercialization</font> of     our products</td>
    </tr>
    <tr>
      <td>Use of <font color="blue">third party</font> <font color="blue">manufacture</font>rs may increase the risk that we will not have     <font color="blue">appropriate</font> supplies of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Reliance on <font color="blue">third party</font> <font color="blue">manufacture</font>rs entails risks to which we would not be     subject  if  we <font color="blue"><font color="blue">manufacture</font>d</font> product <font color="blue">candidates</font> or <font color="blue">products ourselves</font>,     including:       ·       <font color="blue">reliance on</font> the <font color="blue">third party</font> for <font color="blue">regulatory</font> compliance and quality     assurance;       ·       the <font color="blue">possible breach</font> of the <font color="blue">manufacturing</font> <font color="blue">agreement</font> by the third     party; and       ·       the possible <font color="blue">termination</font> or nonrenewal of the <font color="blue">agreement</font> by the third     party, <font color="blue">based on</font> its own business priorities, at a time that is costly or     in<font color="blue">convenient</font> for us</td>
    </tr>
    <tr>
      <td>31     ______________________________________________________________________       If we are not able to obtain <font color="blue">adequate supplies</font> of Angiomax, <font color="blue">clevidipine</font> and     <font color="blue">cangrelor</font>, it will be more <font color="blue">difficult</font> for us to <font color="blue">compete <font color="blue"><font color="blue">effective</font>ly</font></font> and     develop our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Angiomax </font>and our product <font color="blue">candidates</font> may     compete with product <font color="blue">candidates</font> and products of <font color="blue">third parties</font> for access to     <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">contract <font color="blue">manufacture</font>rs</font> are subject to ongoing, periodic, unannounced     <font color="blue">inspection by</font> the FDA and <font color="blue">corresponding</font> state and foreign agencies or their     designees to ensure strict compliance with the FDA’s GMP, <font color="blue">regulations</font> and     other <font color="blue">governmental regulation</font>s and <font color="blue">corresponding</font> foreign standards</td>
    </tr>
    <tr>
      <td>We     cannot be certain that our present or future <font color="blue">manufacture</font>rs will be able to     <font color="blue">comply with</font> GMP <font color="blue">regulations</font> and other FDA <font color="blue">regulatory</font> <font color="blue">requirements</font> or similar     <font color="blue">regulatory</font>  <font color="blue">requirements</font>  outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We do not control     compliance  by  our  <font color="blue">contract <font color="blue">manufacture</font>rs</font> with these <font color="blue">regulations</font> and     standards</td>
    </tr>
    <tr>
      <td>Failure of our <font color="blue">third party</font> <font color="blue">manufacture</font>rs or us to <font color="blue">comply with</font>     applicable  <font color="blue">regulations</font> could result in sanctions being imposed on us,     including  fines,  <font color="blue">injunctions</font>, civil penalties, failure of <font color="blue">regulatory</font>     <font color="blue">authorities</font> to grant <font color="blue">marketing approval</font> of our product <font color="blue">candidates</font>, delays,     suspension or withdrawal of approvals, license revocation, seizures or     recalls  of product <font color="blue">candidates</font> or products, operating <font color="blue">restrictions</font> and     <font color="blue">criminal <font color="blue">prosecutions</font></font>, any of <font color="blue"><font color="blue">which could</font> <font color="blue">significantly</font></font> and <font color="blue">adversely affect</font>     supplies of <font color="blue">Angiomax </font>and our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to our Intellectual Property       A breach of any of the <font color="blue"><font color="blue">agreement</font>s</font> under which we license <font color="blue">commercialization</font>     rights to products or <font color="blue">technology</font> from others could cause us to <font color="blue">lose license</font>     rights that are important to our business or subject us to claims by our     <font color="blue">licensors</font>       We <font color="blue">license rights</font> to products and <font color="blue">technology</font> that are important to our     business, and we expect to enter into <font color="blue">additional</font> licenses in the future</td>
    </tr>
    <tr>
      <td>For     instance, we have <font color="blue"><font color="blue">exclusively</font> licensed patents</font> and patent <font color="blue">application</font>s     relating to <font color="blue">Angiomax </font>from <font color="blue"><font color="blue">Biogen Idec </font>and Health Research Inc</font></td>
    </tr>
    <tr>
      <td>and relating     to <font color="blue">clevidipine</font> and <font color="blue">cangrelor</font> from AstraZeneca</td>
    </tr>
    <tr>
      <td>Under these <font color="blue"><font color="blue">agreement</font>s</font>, we     are subject to <font color="blue">commercialization</font> and <font color="blue">development</font>, sublicensing, royalty,     <font color="blue">patent prosecution</font> and maintenance, insurance and other <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>Any     <font color="blue">failure by us</font> to <font color="blue">comply with</font> any of these <font color="blue">obligations</font> or any other <font color="blue">breach by</font>     us  of  these  license <font color="blue"><font color="blue">agreement</font>s</font> could give the licensor the right to     terminate  the license in whole, terminate the exclusive nature of the     license or bring a claim <font color="blue">against us</font> for damages</td>
    </tr>
    <tr>
      <td>Any such <font color="blue">termination</font> or     claim, <font color="blue">particularly</font> relating to our <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">Biogen Idec </font>and Health     Research Inc, could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Even if     we contest any such <font color="blue">termination</font> or claim and are <font color="blue">ultimately successful</font>, our     <font color="blue">stock price could suffer</font></td>
    </tr>
    <tr>
      <td>In addition, upon any <font color="blue">termination</font> of a license     <font color="blue">agreement</font>,  we  may be required to license to the licensor any related     <font color="blue"><font color="blue">intellectual</font> property</font> that we developed</td>
    </tr>
    <tr>
      <td>If  we  are  unable  to  obtain  or maintain <font color="blue">patent protection</font> for the     <font color="blue"><font color="blue">intellectual</font> property</font> relating to our products, the value of our products     will be <font color="blue"><font color="blue">adversely affect</font>ed</font>       The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> companies like us are <font color="blue">generally</font>     uncertain and involve complex legal, scientific and factual issues</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">success depends <font color="blue">significantly</font> on</font> our ability to:       ·       obtain and maintain US and foreign patents, including defending     those patents against adverse claims;       ·       protect <font color="blue">trade secrets</font>;       ·       operate without infringing the <font color="blue"><font color="blue">proprietary</font> rights</font> of others; and       ·       prevent others from infringing our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>We may not have any <font color="blue">additional</font> patents issued from any patent <font color="blue">application</font>s     that  we own or license</td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> patents are granted, the claims     allowed  may  not  be <font color="blue">sufficiently broad</font> to protect our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In     addition, issued patents that we own or <font color="blue">license may</font> be challenged, narrowed,     invalidated or       32     ______________________________________________________________________       <font color="blue">circumvented</font>,  which  <font color="blue">could limit</font> our ability to stop <font color="blue">competitors</font> from     marketing similar products or limit the length of term of <font color="blue">patent protection</font>     we may have for our products</td>
    </tr>
    <tr>
      <td>Changes in patent laws or in <font color="blue">interpretation</font>s     of patent laws in the <font color="blue"><font color="blue">United States</font> </font>and other <font color="blue">countries may diminish</font> the     value  of  our <font color="blue"><font color="blue">intellectual</font> property</font> or narrow the scope of our patent     protection</td>
    </tr>
    <tr>
      <td>Our <font color="blue">patents also may</font> not afford us protection against <font color="blue">competitors</font> with     similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Because patent <font color="blue">application</font>s in the <font color="blue"><font color="blue">United States</font> </font>and     many foreign <font color="blue">jurisdictions</font> are typically not published until eighteen months     after filing, or in some cases not at all, and because <font color="blue">publications</font> of     <font color="blue">discoveries</font>  in  the  scientific  literature  often  <font color="blue">lag behind actual</font>     <font color="blue">discoveries</font>, neither we nor our <font color="blue">licensors</font> can be certain that others have     not filed or maintained patent <font color="blue">application</font>s for <font color="blue">technology</font> used by us or     <font color="blue">covered by</font> our pending patent <font color="blue">application</font>s without our being aware of these     <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>We  <font color="blue">exclusively</font>  license  US  patents  and  patent  <font color="blue">application</font>s and     <font color="blue">corresponding</font> foreign patents and patent <font color="blue">application</font>s relating to Angiomax,     <font color="blue">clevidipine</font>  and  <font color="blue">cangrelor</font></td>
    </tr>
    <tr>
      <td>As  of the date of this annual report on     Form 10-K,  we <font color="blue">exclusively</font> license six issued US patents relating to     Angiomax, <font color="blue">three issued</font> US patents relating to <font color="blue">clevidipine</font> and four issued     US patents relating to <font color="blue">cangrelor</font></td>
    </tr>
    <tr>
      <td>We have not yet filed any <font color="blue">in<font color="blue">dependent</font></font>     patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>The principal US patent that covers <font color="blue">Angiomax </font>expires     in 2010</td>
    </tr>
    <tr>
      <td><font color="blue">The US Patent and Trademark Office </font>has rejected our <font color="blue">application</font>     for  an  extension  of  the term of the patent beyond 2010 because the     <font color="blue">application</font>  was  not  filed  on time by our counsel</td>
    </tr>
    <tr>
      <td>We are exploring     <font color="blue">alternative</font>s  to  extend the term of the patent, but we can <font color="blue">provide no</font>     assurance that we will be successful</td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> <font color="blue"><font color="blue">agreement</font>s</font> with     the <font color="blue">counsel involved</font> in the filing that suspend the statute of <font color="blue">limitations</font>     on our claims <font color="blue">against them</font> for failing to make a <font color="blue">timely filing</font></td>
    </tr>
    <tr>
      <td>We have     <font color="blue">entered into</font> a similar <font color="blue"><font color="blue">agreement</font> with</font> <font color="blue">Biogen Idec </font>relating to any claims for     damages  and/or license <font color="blue">termination</font> they may bring in the event that a     dispute arises <font color="blue">between us</font> and <font color="blue">Biogen Idec </font>relating to the <font color="blue">late filing</font></td>
    </tr>
    <tr>
      <td>We may be unable to utilize the Chemilog process if UCB Bioproducts breaches     our <font color="blue">agreement</font>       Our <font color="blue"><font color="blue">agreement</font> with</font> UCB Bioproducts for the supply of <font color="blue">Angiomax </font>bulk drug     substance requires that UCB Bioproducts transfer the <font color="blue">technology</font> that was     used to develop the Chemilog process to a <font color="blue">secondary supplier</font> of <font color="blue">Angiomax </font>    bulk drug substance or to us or an <font color="blue">alternate supplier at</font> the expiration of     the  <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>If  UCB  Bioproducts  fails  or is unable to transfer     <font color="blue">successfully</font> this <font color="blue">technology</font>, we would be unable to employ the Chemilog     process to <font color="blue">manufacture</font> our <font color="blue">Angiomax </font>bulk drug substance, <font color="blue">which could</font> cause     us  to experience delays in the <font color="blue">manufacturing</font> process and increase our     <font color="blue">manufacturing</font> costs in the future</td>
    </tr>
    <tr>
      <td>If we are not able to keep our <font color="blue"><font color="blue">trade secrets</font> <font color="blue">confidential</font></font>, our <font color="blue">technology</font>     and information may be <font color="blue">used by others</font> to compete <font color="blue">against us</font>       We rely <font color="blue">significantly</font> upon unpatented <font color="blue">proprietary</font> <font color="blue">technology</font>, information,     processes  and  know-how</td>
    </tr>
    <tr>
      <td>We  seek  to  protect  this  information by     <font color="blue"><font color="blue">confidential</font>ity</font>  <font color="blue"><font color="blue">agreement</font>s</font>  with our employees, <font color="blue">consultants</font> and other     third-party contractors, as well as through other <font color="blue">security measures</font></td>
    </tr>
    <tr>
      <td>We may     not  have  adequate  remedies  for  any  breach  by  a  party to these     <font color="blue"><font color="blue">confidential</font>ity</font>  <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">competitors</font> may learn or     <font color="blue">in<font color="blue">dependent</font></font>ly develop our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">confidential</font> information or     <font color="blue">trade secrets</font> become publicly known, they may lose their value to us</td>
    </tr>
    <tr>
      <td>If we infringe or are alleged to infringe <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> of     <font color="blue">third parties</font>, it will <font color="blue">adversely affect</font> our business       Our research, <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">activities</font>, as well as any     product <font color="blue">candidates</font> or products resulting from these <font color="blue">activities</font>, may infringe     or be claimed to <font color="blue">infringe patents</font> or patent <font color="blue">application</font>s under which we do     not hold licenses or other rights</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> own or control these     patents and patent <font color="blue">application</font>s in the <font color="blue"><font color="blue">United States</font> </font>and abroad</td>
    </tr>
    <tr>
      <td>These third     <font color="blue">parties could bring</font> claims <font color="blue">against us</font> or our <font color="blue">collaborators</font> that would cause     us to incur substantial expenses and, if successful <font color="blue">against us</font>, could cause     us to pay substantial damages</td>
    </tr>
    <tr>
      <td>Further, if a <font color="blue">patent infringement suit</font> were     <font color="blue">brought against</font>       33     ______________________________________________________________________       us  or  our <font color="blue">collaborators</font>, we or they could be forced to stop or delay     research, <font color="blue">development</font>, <font color="blue">manufacturing</font> or sales of the product or product     candidate that is the subject of the suit</td>
    </tr>
    <tr>
      <td>As a result of patent infringement claims, or in order to <font color="blue">avoid potential</font>     claims, we or our <font color="blue"><font color="blue">collaborators</font> may</font> choose or be required to seek a license     from the <font color="blue">third party</font> and be required to <font color="blue">pay license fees</font> or royalties or     both</td>
    </tr>
    <tr>
      <td>These <font color="blue">licenses may</font> not be <font color="blue">available on</font> acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Even if we or our <font color="blue">collaborators</font> were able to obtain a license, the rights     may be nonexclusive, <font color="blue">which could</font> result in our <font color="blue">competitors</font> gaining access to     the same <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>Ultimately, we could be <font color="blue">prevented from</font>     <font color="blue">commercializing</font> a product, or be forced to cease some aspect of our business     <font color="blue">operations</font>, if, as a result of actual or <font color="blue">threatened patent infringement</font>     claims,  we  or our <font color="blue">collaborators</font> are unable to <font color="blue">enter into licenses on</font>     acceptable terms</td>
    </tr>
    <tr>
      <td>This <font color="blue">could harm</font> our business <font color="blue">significantly</font></td>
    </tr>
    <tr>
      <td>There has been substantial <font color="blue">litigation</font> and other <font color="blue">proceedings</font> regarding patent     and  other  <font color="blue">intellectual</font>  property  rights  in  the <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> industries</td>
    </tr>
    <tr>
      <td>In addition to infringement claims <font color="blue">against us</font>, we     may  become  a party to other patent <font color="blue">litigation</font> and other <font color="blue">proceedings</font>,     including interference <font color="blue">proceedings</font> declared by the US Patent and Trademark     Office and opposition <font color="blue">proceedings</font> in the European Patent Office, regarding     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> with respect to our products and <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The  cost  to us of any patent <font color="blue">litigation</font> or other proceeding, even if     resolved in our favor, could be substantial</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> may be     able to sustain the costs of such <font color="blue">litigation</font> or <font color="blue">proceedings</font> more <font color="blue"><font color="blue">effective</font>ly</font>     than we can because of their <font color="blue">substantially</font> greater financial resources</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting from the <font color="blue">initiation</font> and <font color="blue">continuation</font> of patent     <font color="blue">litigation</font> or other <font color="blue">proceedings</font> could have a material adverse effect on our     ability  to  compete  in  the marketplace</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> and other     <font color="blue">proceedings</font> may also absorb significant <font color="blue">management</font> time</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to Growth and Employees       If we fail to acquire and develop <font color="blue">additional</font> product <font color="blue">candidates</font> or approved     products it will impair our ability to grow       We  have a <font color="blue">single product approved</font> for marketing</td>
    </tr>
    <tr>
      <td>In order to generate     <font color="blue">additional</font> revenues, we intend to acquire and develop <font color="blue">additional</font> product     <font color="blue">candidates</font> or <font color="blue">approved products</font></td>
    </tr>
    <tr>
      <td>The success of this <font color="blue">growth strategy depends</font>     upon our ability to identify, select and acquire <font color="blue">pharmaceutical</font> products     that meet the criteria we have established</td>
    </tr>
    <tr>
      <td>Because we neither have, nor     intend to establish, internal scientific research <font color="blue">capabilities</font>, we are     <font color="blue">dependent</font>  upon  <font color="blue">pharmaceutical</font>  and <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font> and other     <font color="blue">researchers</font> to sell or license product <font color="blue">candidates</font> to us</td>
    </tr>
    <tr>
      <td>We will be required     to integrate any acquired <font color="blue">products into</font> our existing <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Managing     </font>the <font color="blue">development</font> of a <font color="blue">new product entails numerous financial</font> and operational     risks, including <font color="blue">difficult</font>ies in <font color="blue">attracting qualified employees</font> to develop     the product</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">product candidate</font> we acquire will require <font color="blue">additional</font> research and     <font color="blue">development</font>  efforts  prior  to  commercial  sale, including extensive     pre-clinical  and/or  clinical  testing  and  approval  by the FDA and     <font color="blue">corresponding</font> foreign <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>All product <font color="blue">candidates</font> are     prone  to  the  risks  of  failure  inherent in <font color="blue">pharmaceutical</font> product     <font color="blue">development</font>, including the <font color="blue">possibility</font> that the <font color="blue">product candidate</font> will not     be safe and <font color="blue">effective</font> or <font color="blue">approved by</font> <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">cannot assure</font> you that any <font color="blue">approved products</font> that we develop     or acquire will be:       ·       <font color="blue"><font color="blue">manufacture</font>d</font> or produced <font color="blue">economically</font>;       ·       <font color="blue">successfully</font> <font color="blue">commercialize</font>d; or       ·       <font color="blue">widely accepted</font> in the marketplace</td>
    </tr>
    <tr>
      <td>We have <font color="blue">previously</font> acquired rights to products and, after having conducted     <font color="blue">development</font> <font color="blue">activities</font>, determined not to <font color="blue">devote further resources</font> to those     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any <font color="blue">additional</font> products that we acquire     will be <font color="blue">successfully</font> developed</td>
    </tr>
    <tr>
      <td>34     ______________________________________________________________________       In addition, proposing, negotiating and <font color="blue">implementing</font> an <font color="blue">economically</font> viable     <font color="blue">acquisition</font> is a lengthy and <font color="blue">complex process</font></td>
    </tr>
    <tr>
      <td>Other companies, including     those with <font color="blue">substantially</font> greater financial, marketing and <font color="blue">sales resources</font>,     <font color="blue">may compete with</font> us for the <font color="blue">acquisition</font> of product <font color="blue">candidates</font> and approved     products</td>
    </tr>
    <tr>
      <td>We may not be able to acquire the rights to <font color="blue">additional</font> product     <font color="blue">candidates</font> and <font color="blue">approved products</font> on terms that we find acceptable, or at     all</td>
    </tr>
    <tr>
      <td>We may undertake strategic <font color="blue">acquisition</font>s in the future and any <font color="blue">difficult</font>ies     from integrating such <font color="blue">acquisition</font>s could damage our ability to attain or     maintain <font color="blue">profitability</font>       We may acquire <font color="blue">additional</font> <font color="blue">businesses</font> and products that <font color="blue">complement</font> or augment     our existing business</td>
    </tr>
    <tr>
      <td><font color="blue">Integrating </font>any newly acquired business or product     could be expensive and time-consuming</td>
    </tr>
    <tr>
      <td>We may not be able to integrate any     acquired business or product <font color="blue">successfully</font> or operate any acquired business     profitably</td>
    </tr>
    <tr>
      <td>Moreover, we may need to raise <font color="blue">additional</font> funds through public     or <font color="blue">private debt</font> or <font color="blue">equity financing</font> to acquire any <font color="blue">businesses</font> or products,     which  may  result  in  dilution for <font color="blue">stockholders</font> or the incurrence of     <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>We may not be able to manage our business <font color="blue"><font color="blue">effective</font>ly</font> if we are unable to     attract and retain <font color="blue">key personnel</font> and <font color="blue">consultants</font>       Our industry has experienced a high rate of turnover of <font color="blue">management</font> personnel     in <font color="blue">recent years</font></td>
    </tr>
    <tr>
      <td>We are highly <font color="blue"><font color="blue">dependent</font> on</font> our ability to attract and     retain  qualified  personnel  for  the  <font color="blue">acquisition</font>,  <font color="blue">development</font>  and     <font color="blue">commercialization</font> <font color="blue">activities</font> we conduct or sponsor</td>
    </tr>
    <tr>
      <td>If we lose one or more     of the members of our senior <font color="blue">management</font>, including our Chairman and Chief     Executive Officer, Clive A Meanwell, or our President and Chief Operating     Officer, John P Kelley, or other <font color="blue">key employees</font> or <font color="blue">consultants</font>, our ability     to implement <font color="blue">successfully</font> our business <font color="blue">strategy could</font> be <font color="blue">seriously harmed</font></td>
    </tr>
    <tr>
      <td>Our ability to replace these <font color="blue">key employees</font> may be <font color="blue">difficult</font> and may take an     <font color="blue">extended period</font> of time because of the limited number of <font color="blue">individuals</font> in our     <font color="blue">industry with</font> the breadth of skills and experience required to acquire,     develop and <font color="blue">commercialize</font> products <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>to hire from     this limited pool is intense, and we may be unable to hire, train, retain or     motivate such <font color="blue">additional</font> personnel</td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate governance structure</font>, including provisions in our <font color="blue">certificate</font>     of <font color="blue">incorporation</font> and by-laws and <font color="blue">Delaware </font>law, may prevent a change in     control or <font color="blue">management</font> that <font color="blue">security holders may</font> consider desirable       Section 203 of the General Corporation Law of the State of <font color="blue">Delaware </font>and our     <font color="blue">certificate</font> of <font color="blue">incorporation</font> and by-laws contain provisions that might     enable our <font color="blue">management</font> to resist a takeover of our company or discourage a     <font color="blue">third party</font> from attempting to take over our company</td>
    </tr>
    <tr>
      <td>These provisions     include the <font color="blue">inability</font> of <font color="blue">stockholders</font> to act <font color="blue">by written consent</font> or to call     <font color="blue">special meetings</font>, a <font color="blue">classified board</font> of <font color="blue">directors</font> and the ability of our     board  of  <font color="blue">directors</font> to designate the terms of and <font color="blue">issue new series</font> of     <font color="blue">preferred stock without stockholder approval</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could</font> have the effect of delaying, deferring, or preventing     a change in control of us or a change in our <font color="blue">management</font> that <font color="blue">stockholders</font>     may consider favorable or <font color="blue">beneficial</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could</font> also discourage     proxy  contests  and  make it more <font color="blue">difficult</font> for <font color="blue">stockholders</font> to elect     <font color="blue">directors</font> and take other <font color="blue">corporate actions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could</font> also     limit the price that investors might be willing to pay in the future for     shares of our <font color="blue">common stock</font> or our other securities</td>
    </tr>
  </tbody>
</table>